Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.41% | -8.26% | -12.33% | 15.35% | -3.70% |
| Total Depreciation and Amortization | -15.24% | -14.05% | -0.54% | 8.71% | 9.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 171.04% | 164.93% | 126.75% | -348.98% | -679.21% |
| Change in Net Operating Assets | -56.75% | -16.26% | 99.07% | 185.89% | 801.23% |
| Cash from Operations | 9.68% | 10.46% | 6.71% | 11.42% | 1.01% |
| Capital Expenditure | 81.42% | -288.71% | -2,869.49% | -5,670.00% | -1,411.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | 200.84% |
| Cash from Investing | -100.57% | -101.40% | -101.17% | -540.46% | 197.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.94% | 14.91% | 14.50% | 13.09% | 6.27% |
| Issuance of Common Stock | -40.51% | -58.18% | -76.76% | -89.54% | 62.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,658.10% | -939.45% | -- | 173.14% | 117.71% |
| Cash from Financing | -48.00% | -62.85% | -79.79% | -86.19% | 66.10% |
| Foreign Exchange rate Adjustments | -97.26% | 717.07% | 403.98% | 154.61% | -43.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -231.88% | -200.70% | -179.93% | -356.87% | 147.02% |